Delaware Senate Approves Bill Allowing Medical Cannabis Use in Hospitals

13 March 2026

Delaware’s approach to medical cannabis may soon shift in hospital settings following legislative action on Senate Bill 226. The measure, introduced to amend state law governing medical marijuana, is intended to allow terminally ill patients to use cannabis while receiving care in licensed acute care hospitals. After securing approval from the Senate Health and Social Services Committee, the bill passed the full Senate on March 12.

Supporters of the proposal argue that it addresses a gap in Delaware’s medical marijuana card system, which has operated since 2011 but has not provided explicit protections for patients seeking to use cannabis in institutional environments. In practice, hospitals have often prohibited cannabis use, even for individuals with qualifying conditions such as cancer or HIV related complications. The legislation’s focus on terminally ill patients reflects an attempt to balance compassionate care considerations with clinical oversight.

Under the bill’s provisions, patients and caregivers would be responsible for obtaining and administering cannabis, with requirements to store the medication securely and notify attending physicians. Hospitals would be required to maintain documentation of patient use and develop written policies outlining procedures for cannabis consumption within their facilities. Smoking or vaping cannabis would not be allowed, meaning patients would need to rely on alternative forms such as oils or edibles.

Healthcare providers would retain discretion to prohibit cannabis use if it poses a risk to treatment outcomes or conflicts with federal guidance. Facilities could also suspend authorization if federal agencies take enforcement actions or issue directives explicitly restricting cannabis use in healthcare settings. The policy would not apply to emergency department patients, further narrowing its scope.

The legislation’s progression comes amid broader developments in Delaware’s cannabis landscape. Adult use sales began in 2024 following voter approval of legalization in 2022, and lawmakers have continued to review regulatory challenges, including zoning restrictions and public consumption penalties. While the state’s regulated market has expanded access and generated revenue, medical patients have faced unique barriers in institutional care contexts.

For patients and families navigating end of life treatment, the proposed change may offer an additional pathway for symptom management. Yet practical questions remain, particularly around how hospitals will integrate cannabis protocols alongside existing compliance frameworks tied to federal funding. As the bill advances to the House for consideration, its ultimate impact may depend on how healthcare institutions interpret and implement the new requirements.